Proteomic study of breast cancer cell line after hemeoxygenase-1 modulation by hemin treatment

SCHWEITZER, K.; FERNÁNDEZ CHÁVEZ, L.; ALONSO, E.G.; MASCARÓ, M.; ORESTI, G.M.; BORISOV, A.; FACCHINETTI, M.M.; CURINO, A.C.; FÄSSLER, R.; COLÓ, G.P. ; GANDINI, N.A.

Mar del Plata

Congreso; Reunión annual de SAIC, SAFE, SAB, SAP; 2019

Hemeoxygenase-1 (HO-1) is a microsomal enzyme that catalyzes the degradation of the heme group and it can betranslocated to multiple subcellular compartments. Our laboratory, among others, has shown that HO-1 regulatesseveral processes related to cancer progression such as: proliferation/apoptosis, migration, invasion, metastasis and theepithelial-mesenchymal transition (EMT). The aim of this work is to investigate the role of HO-1 in the proteomemodulation in a breast cancer cell line. Protein extracts of LM3 cell line treated with hemin, a pharmacological HO-1inducer (80 µM, 24h), were obtained and studied by Western blot and Mass spectrometry (MS). MS-data analysisshowed that 1033 from 7292 proteins were modulated after hemin treatment (ANOVA p